Fitusiran + Clotting factor concentrates (CFC) or bypassing agents (BPA) + Antithrombin concentrate (ATIIIC)

Phase 3Recruiting

0 views this week 0 watching⚡ Active💊Featured in Rare Disease Pipeline Watch

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hemophilia

Conditions

Hemophilia

Trial Timeline

Dec 18, 2025 → Dec 30, 2031

NCT ID

NCT07285460

About Fitusiran + Clotting factor concentrates (CFC) or bypassing agents (BPA) + Antithrombin concentrate (ATIIIC)

Fitusiran + Clotting factor concentrates (CFC) or bypassing agents (BPA) + Antithrombin concentrate (ATIIIC) is a phase 3 stage product being developed by Sanofi for Hemophilia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07285460. Target conditions include Hemophilia.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia were approved

Approved (20) Terminated (3) Active (0)

✅EmicizumabRocheApproved

✅BenefixPfizerApproved

✅Nonacog alfaPfizerApproved

✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved

✅Recombinant Factor IX CoagulationPfizerApproved

✅Moroctocog alfa(AF-CC)PfizerApproved

✅Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07285460	Phase 3	Recruiting	Dec 18, 2025	Dec 30, 2031	Hemophilia
NCT05662319	Phase 3	Active	Feb 1, 2023	Jan 25, 2029	Hemophilia

Competing Products

20 competing products in Hemophilia

See all competitors

Product	Company	Stage	Hype Score
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab + rFVIIa + aPCC	Chugai Pharmaceutical	Phase 3	40
Human Coagulation Factor VIII	Chugai Pharmaceutical	Phase 3	47
Emicizumab	Chugai Pharmaceutical	Phase 3	47
Emicizumab + Factor VIII (FVIII)	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Roche	Phase 3	40
HEMLIBRA	Johnson & Johnson	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Emicizumab	Roche	Approved	47
Emicizumab	Roche	Phase 3	44
SPK-8011QQ	Roche	Phase 1/2	39
NXT007	Roche	Phase 1/2	39
Emicizumab Injection	Roche	Phase 2	35
Bypassing Agents + FVIII Replacement	Roche	Pre-clinical	26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086	Pfizer	Phase 2	35
Nonacog Alfa (Genetical Recombination)	Pfizer	Pre-clinical	26
Refacto AF	Pfizer	Pre-clinical	18
PF-06838435/ fidanacogene elaparvovec	Pfizer	Phase 3	44
ReFacto AF	Pfizer	Phase 3	40